0IL8 Stock Chart & Stats
$7.96
-$0.27(-3.62%)
At close: 4:00 PM EDT
$7.96
-$0.27(-3.62%)
Day’s Range― - ―
52-Week Range$6.29 - $12.55
Previous CloseN/A
Volume211.00
Average Volume (3M)662.00
Market Cap
$28.65M
Enterprise Value-$38.76
Total Cash (Recent Filing)$91.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.1
Beta0.79
Next Earnings
Nov 09, 2026EPS Estimate
-3.73Next Dividend Ex-DateN/A
Dividend Yield0.02%
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume399
30 Day Avg. Volume662
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$39.67Price Target Upside398.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.4
Revenue Forecast (FY)$6.77M
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressThe advancing FG-3246 Phase II study provides a defined development path and a measurable clinical catalyst within the next several months. Earlier response and progression-free-survival signals support continued testing, while the trial design can clarify dose, safety, and efficacy for later-stage planning.
Roxadustat Phase III ReadinessA finalized Phase III protocol moves roxadustat beyond exploratory development and creates a potential second value-generating program. The reported high-transfusion-burden subgroup result offers clinical support for registration planning, although execution and funding decisions remain important.
Reduced Future Financing ObligationsLowering the maximum financing payments and eliminating true-up obligations should reduce future liability pressure and improve capital-allocation flexibility. The agreement also caps remaining obligations at $15 million, allowing Kyntra to retain subsequent royalties after that cap is reached.
Bears Say
Revenue ContractionSharp revenue contraction indicates that current operations are not producing a stable or growing commercial base. For a therapeutics developer, weaker revenue can increase reliance on financing, royalties, or successful clinical milestones to fund research and sustain the business over the coming quarters.
Persistent Cash Burn And Negative EquityNegative free cash flow shows that the business continues consuming cash rather than funding development internally, while negative equity indicates an accumulated deficit and limited capital cushion. Together, these conditions can constrain flexibility and make future funding needs more consequential.
Clinical And Funding Execution RiskKyntra’s medium-term prospects depend on confirming early clinical signals in larger studies and managing known safety issues as dosing advances. Roxadustat also may require a partner or additional capital, which could dilute economics or delay development if funding is not secured.
Kyntra Bio News
0IL8 FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest share price was $6.29 and its highest was $12.54 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $28.65M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Nov 09, 2026 which is in 49 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.02%. See more information on Kyntra Bio dividends here
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.73.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went down -1.367%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in GB:0IL8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
0IL8 Company Deck
0IL8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all GB:0IL8 earnings summaries0IL8 Stock 12 Month Forecast
Average Price Target
$39.67
▲(398.32% Upside)
Technical Analysis
Grace Therapeutics
―
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―